Published in Eur Urol on May 12, 2012
Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk. Urology (2015) 1.97
Associations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer. Eur Urol (2015) 1.47
Do environmental factors modify the genetic risk of prostate cancer? Cancer Epidemiol Biomarkers Prev (2014) 1.42
Evaluation of reported prostate cancer risk-associated SNPs from genome-wide association studies of various racial populations in Chinese men. Prostate (2013) 1.00
Genetic score is an objective and better measurement of inherited risk of prostate cancer than family history. Eur Urol (2012) 1.00
Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs. Prostate (2013) 0.98
Prostate cancer risk-associated genetic markers and their potential clinical utility. Asian J Androl (2013) 0.97
Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes. Prostate (2013) 0.96
Risk prediction for sporadic Alzheimer's disease using genetic risk score in the Han Chinese population. Oncotarget (2015) 0.91
Prostate cancer risk alleles are associated with prostate cancer volume and prostate size. J Urol (2013) 0.90
The Xu's chart for prostate biopsy: a visual presentation of the added value of biomarkers to prostate-specific antigen for estimating detection rates of prostate cancer. Asian J Androl (2014) 0.88
Do African-American men need separate prostate cancer screening guidelines? BMC Urol (2016) 0.85
Estimating the predictive ability of genetic risk models in simulated data based on published results from genome-wide association studies. Front Genet (2014) 0.83
Clinical validity and utility of genetic risk scores in prostate cancer. Asian J Androl (2016) 0.82
Current early diagnostic biomarkers of prostate cancer. Asian J Androl (2014) 0.81
Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer. Asian J Androl (2016) 0.81
Improved prediction of complex diseases by common genetic markers: state of the art and further perspectives. Hum Genet (2016) 0.80
Multiplex pyrosequencing assay using AdvISER-MH-PYRO algorithm: a case for rapid and cost-effective genotyping analysis of prostate cancer risk-associated SNPs. BMC Med Genet (2015) 0.80
Ratio of prostate specific antigen to the outer gland volume of prostrate as a predictor for prostate cancer. Int J Clin Exp Pathol (2014) 0.79
Personalized prostate cancer care: from screening to treatment. Asian J Androl (2016) 0.79
A genetic-based approach to personalized prostate cancer screening and treatment. Curr Opin Urol (2015) 0.79
Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases. Asian J Androl (2016) 0.79
A comparison of genetic risk score with family history for estimating prostate cancer risk. Asian J Androl (2016) 0.79
Genome-wide association studies on prostate cancer: the end or the beginning? Protein Cell (2013) 0.79
Influence of age on predictiveness of genetic risk score for prostate cancer in a Chinese hospital-based biopsy cohort. Oncotarget (2015) 0.77
Will biomarkers save prostate cancer screening? Eur Urol (2012) 0.77
The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. Oncologist (2016) 0.76
An Integrative Genomics Approach for Associating Genome-Wide Association Studies Information With Localized and Metastatic Prostate Cancer Phenotypes. Biomark Insights (2017) 0.75
Genetic scores based on risk-associated single nucleotide polymorphisms (SNPs) can reveal inherited risk of renal cell carcinoma. Oncotarget (2016) 0.75
Multigene panels in prostate cancer risk assessment: a systematic review. Genet Med (2015) 0.75
Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator. J Urol (2014) 0.75
Prostate cancer: does genetic score justify early prostate biopsy? Nat Rev Urol (2013) 0.75
Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview. Int Sch Res Notices (2014) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making (2006) 11.83
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med (2008) 9.64
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet (2009) 5.06
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res (2002) 3.78
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Genome-wide association studies in cancer. Hum Mol Genet (2008) 3.34
Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak (2008) 2.64
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62
PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol (2010) 2.33
Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate (2009) 1.99
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate (2009) 1.95
Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate (2009) 1.83
Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation. Prostate (2010) 1.67
Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin Cancer Res (2009) 1.49
Repeat prostate biopsy--when, where, and how. Urol Oncol (2009) 1.09
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Human-mouse alignments with BLASTZ. Genome Res (2003) 35.49
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. Genome Res (2009) 15.15
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med (2010) 14.49
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med (2004) 11.46
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90
Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med (2008) 9.68
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Incidence of diabetes in youth in the United States. JAMA (2007) 8.70
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med (2007) 8.59
Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation (2005) 8.54
Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 8.49
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest (2006) 8.43
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J (2013) 8.39
Application of new cholesterol guidelines to a population-based sample. N Engl J Med (2014) 8.22
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Rapid whole-genome mutational profiling using next-generation sequencing technologies. Genome Res (2008) 8.01
An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet (2009) 7.27
The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics (2006) 7.19
Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med (2009) 7.17
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA (2007) 6.95
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med (2002) 6.92
Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA (2002) 6.84
Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation (2003) 6.83
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet (2012) 6.79
Obesity and the risk of new-onset atrial fibrillation. JAMA (2004) 6.73
Simultaneous analysis of all SNPs in genome-wide and re-sequencing association studies. PLoS Genet (2008) 6.66
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med (2004) 6.42
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol (2007) 6.33
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med (2010) 6.19
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation (2006) 5.97
Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med (2011) 5.94
Prostate cancer. N Engl J Med (2003) 5.91
Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation (2007) 5.87
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (2012) 5.82
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet (2007) 5.64
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA (2004) 5.34
Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab (2006) 5.33
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol (2007) 5.24
The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet (2007) 5.02
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA (2004) 4.85
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA (2013) 4.81
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA (2003) 4.77
Trends in cardiovascular complications of diabetes. JAMA (2004) 4.74
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA (2004) 4.63
Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med (2008) 4.63
Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation (2009) 4.62
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 4.62
A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med (2008) 4.61